HKEX Ushers in Chapter 18C Era with XtalPi's Listing; Inner Mongolia Cracks Down on $7 Billion Medical VAT Invoice Fraud
XtalPi
Computation-Driven Innovative Drug R&D Provider
Jacobio
Innovative Drug Developer
VectorBuilder
Gene Delivery Technology Developer
Bioperfectus Technologies
Molecular Diagnostics Product Developer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
Consun
Pharmaceutical Manufacturer
HKEX ushers in the 18C New Era.
On June 13, XtalPi, a leading company in the AI-driven intelligent manufacturing sector, officially listed on the Hong Kong Stock Exchange, becoming the first technology company to go public under Rule 18C. This marks a new chapter for pharmaceutical industry enterprises utilizing Rule 18C for their listings. In the future, we look forward to seeing which other pharmaceutical companies will also enter the 18C market segment.
Pharmaceutical enterprises need to be vigilant in invoice management.
According to a report by Xinhua News Agency on June 13, the Wulanhaote Public Security Bureau in Xing'an League, Inner Mongolia Autonomous Region, recently successfully cracked a major case of fraudulent issuance of value-added tax invoices in the pharmaceutical sector, involving an amount as high as 5 billion yuan. Thirty-two suspects have been arrested.
It began in January 2024, when the Wulanhaote Public Security Bureau discovered anomalies during routine work: more than 30 companies, without any actual business transactions, were frequently issuing fake VAT invoices to pharmaceutical manufacturing enterprises. Preliminary investigations revealed that the companies involved spanned multiple provinces, employing covert methods, with an extremely large amount of money involved.
In the past day, what are the hot topics in the pharmaceutical markets at home and abroad that are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Jacobio Appoints Vice President of Clinical Pharmacology
On June 13, Jacobio announced the appointment of Dr. Xiao Jianjun as Vice President of Clinical Pharmacology. He will be based in Boston, leading Jacobio's global clinical pharmacology team.
2) Livzon Pharmaceuticals Introduces Xuanzhu Bio's PDE5 Inhibitor
On June 13, Siho Med announced that its non-wholly owned subsidiary, Xuanzhu Bio, had reached a cooperation agreement with Livzon Med. Livzon Med obtained the exclusive rights for the development, production, and commercialization of the PDE5 inhibitor, Revatio (Sildenafil), in Greater China and non-regulated market regions.
/ 02 /
Capital Information
1) VectorBuilder Terminates Sci-Tech Innovation Board IPO
On June 13, the sponsor of VectorBuilder, Haitong Securities, applied to withdraw its sponsorship, and the Shanghai Stock Exchange decided to terminate the review of VectorBuilder's initial public offering and listing on the STAR Market.
2) XtalPi Holdings Limited Listed on HKEX
On June 13, XtalPi, the first AI-driven intelligent manufacturing stock, officially listed on the Hong Kong Stock Exchange, becoming the first technology company to go public under Rule 18C.
/ 03 /
Pharmaceuticals and Medical Devices News
1) Bioperfectus Technologies' testing products receive EU CE certification
On June 13, Bioperfectus Technologies announced that nine of its products, including the Plasmodium DNA Real-Time PCR Detection Kit, had recently obtained CE certification under EU Regulation (EU) 2017/746. After obtaining this certification, the products can be sold in EU countries and other countries that recognize EU CE certification.
2) AstraZeneca's Balcinrenone Dapagliflozin Capsules Approved for Clinical Use
On June 13, according to the CDE official website, AstraZeneca's Balcinrenone Dapagliflozin Capsules have been approved for clinical trials, intended for use in patients with chronic kidney disease and proteinuria.
3) Consun's SK-08 Tablets Approved for Clinical Trials
On June 13, according to the CDE official website, Consun's SK-08 tablet has been approved for clinical trials for the treatment of chronic kidney disease.
4) Sumitomo Pharma's Lafermin Acetate Tablets Proposed for Priority Review
On June 13, according to the CDE official website, Sumitomo Pharma's Lefamulin Acetate Tablets are proposed for priority review, indicated for the treatment of adult community-acquired pneumonia.
5) Novartis JAK Inhibitor Receives Approval for New Indication
On June 13, Novartis announced that the new indication for the JAK inhibitor Jakavi (ruxolitinib) has been approved for the treatment of chronic graft-versus-host disease (cGVHD) patients aged 12 years and older who have had an inadequate response to corticosteroids or other systemic therapies.
6) Innovent Biologics' CLDN18.2 ADC Granted FDA Fast Track Designation,
On June 13, Innovent Biologics announced that the CLDN18.2 ADC drug IBI343 had been granted Fast Track designation by the U.S. FDA. The proposed indication is for patients with CLDN18.2-positive advanced pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy.
/ 04 /
Overseas Pharmaceutical News
1) Pfizer's DMD Gene Therapy Phase III Study Fails
On June 12, Pfizer announced that the Phase III CIFFREO study of gene therapy Fordadistrogene movaparvovec (PF-06939926) for the treatment of Duchenne Muscular Dystrophy (DMD) did not meet its primary endpoint.
Text / Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Amino for communication.
